IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Average Target Price of $747.00 According to Brokerages

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $747.00.

Several equities analysts have weighed in on IDXX shares. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Barclays decreased their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Finally, UBS Group lifted their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $506.67 on Monday. The firm has a fifty day moving average of $540.69 and a two-hundred day moving average of $553.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The stock has a market capitalization of $39.92 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 2.75 and a beta of 1.55. IDEXX Laboratories has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period last year, the company earned $3.50 EPS. The firm’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts predict that IDEXX Laboratories will post 14.81 EPS for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in IDXX. Aurora Investment Managers LLC. acquired a new position in IDEXX Laboratories during the second quarter worth $2,442,000. NewEdge Advisors LLC increased its stake in IDEXX Laboratories by 60.9% in the 1st quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock valued at $8,552,000 after buying an additional 5,761 shares during the last quarter. National Pension Service increased its stake in IDEXX Laboratories by 5.6% in the 2nd quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after buying an additional 6,885 shares during the last quarter. Arizona State Retirement System lifted its position in IDEXX Laboratories by 4.9% during the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock worth $11,988,000 after buying an additional 1,074 shares in the last quarter. Finally, SVB Wealth LLC lifted its position in IDEXX Laboratories by 17.4% during the 1st quarter. SVB Wealth LLC now owns 7,335 shares of the company’s stock worth $4,121,000 after buying an additional 1,089 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.